Held annually alongside Biotech Showcase and OneMed Forum, the JP Morgan conference is one of the largest and most informative healthcare symposiums in the industry. BioSim will be meeting throughout the conference to update suppliers and interested parties on state of their research and development program.
BioSim’s ACTH Gelatin Depot 80 IU/mL product is a copy of the branded drug H.P. ACTHAR®, manufactured by Mallinckrodt Plc (NYSE: MNK) which in 2014 purchased the previous owner, Questcor Pharmaceuticals (NASDAQ:QCOR) through a tax inversion valued at over $5 billion dollars. The injectable drug treats infantile spasms and rare autoimmune disorders like nephrotic syndrome and multiple sclerosis. BioSim has been advancing its ACTH (Corticotropin) Gel since 2012. With significant research and development, coupled with recent government guidance, its product has been demonstrated in-vitro and in-vivo to perform like ACTHAR.
Over the past few decades, the market for specialty biopharmaceutical products for rare diseases has blossomed. For established companies like Teva (NYSE:Teva) and Cipla (NSE: CIPLA), as well as niche players like Depomed and Zydus Cadilla (NSE: CADILAHC), the US market continues to see rapid growth. BioSim has positioned itself to take advantage of that change, all with the goal of lowering the cost of medicine for America’s Healthcare System.
For parties interested in securing a meeting with BioSim, please contact bizdev@biosimllc.com.
About BioSim Pharmaceuticals
BioSim, a Seattle-based pharmaceutical company started in early 2012, is focused on building a portfolio around hard to copy generic drugs and biologics for the orphan disease market. For more information, visit www.biosimpharmaceuticals.com
H.P. ACTHAR® is a registered trademark of Mallinckrodt.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005704/en/
Contacts:
Candy Coates, 206-552-0630
press@biosimllc.com
